ImageneBio IMA
NASDAQ IMA
$4.05 -0.04 (-0.98%)
At close: Oct 22, 2026 · 4:00 PM EDT

ImageneBio (IMA) Gains from Sales and Divestitures (2024)

Updated

ImageneBio (IMA) reported Gains from Sales and Divestitures of $1.19 million for Q4 2024.

Analysis

ImageneBio (IMA) Gains from Sales and Divestitures (2024) Analysis & Trends

For FY2024, ImageneBio posted Gains from Sales and Divestitures of -$99,000.

  • By year, Gains from Sales and Divestitures came in at -$5,000 in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,144.36 Bn 1,112.95 Bn 19.71 Bn
2 Johnson & Johnson 635.36 Bn 555.22 Bn 17.30 Bn
3 AbbVie 502.79 Bn 475.90 Bn 12.70 Bn
4 Merck 356.08 Bn 310.46 Bn 12.21 Bn
5 Novartis Ag 300.87 Bn 264.86 Bn 11.24 Bn
6 Astrazeneca 264.31 Bn 237.99 Bn 12.86 Bn
7 Amgen 239.07 Bn 194.47 Bn 7.24 Bn
8 Gilead Sciences 194.50 Bn 168.70 Bn 6.22 Bn
9 Pfizer 171.00 Bn 117.64 Bn 10.94 Bn
10 ImageneBio 34.53 Mn -453.09 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 1.19 Mn
Sep 30, 2024 -1.19 Mn
Mar 31, 2024 -99,000.00
API Access

ImageneBio Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=IMA&period=max&api_key=YOUR_API_KEY